Hologic, Inc. (NASDAQ:HOLX) Receives $84.62 Consensus PT from Brokerages

Hologic, Inc. (NASDAQ:HOLX - Get Free Report) has been assigned an average rating of "Hold" from the seventeen ratings firms that are covering the stock, MarketBeat reports. Eleven analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $84.62.

HOLX has been the subject of a number of research analyst reports. Needham & Company LLC downgraded Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target for the company. in a research report on Monday, February 3rd. Royal Bank of Canada decreased their target price on Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research report on Thursday, February 6th. Morgan Stanley cut their price target on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Argus downgraded shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Finally, Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th.

Hologic Stock Up 0.5 %

HOLX traded up $0.28 during midday trading on Friday, hitting $58.36. The company had a trading volume of 1,552,009 shares, compared to its average volume of 1,967,219. The company has a market capitalization of $13.10 billion, a price-to-earnings ratio of 18.41, a PEG ratio of 2.14 and a beta of 0.82. The stock's 50 day moving average price is $60.90 and its 200 day moving average price is $69.77. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic has a 52 week low of $55.89 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts anticipate that Hologic will post 4.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hologic

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in shares of Hologic by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock valued at $412,159,000 after purchasing an additional 144,838 shares during the period. Victory Capital Management Inc. increased its position in shares of Hologic by 0.5% during the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider's stock valued at $354,506,000 after buying an additional 24,358 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Hologic by 3.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider's stock worth $322,272,000 after buying an additional 129,035 shares in the last quarter. Invesco Ltd. boosted its position in shares of Hologic by 16.4% in the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock valued at $293,434,000 after acquiring an additional 572,187 shares during the period. Finally, Boston Partners grew its stake in Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after acquiring an additional 1,602,463 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.